Published in Cancer Weekly, September 7th, 2004
"The antineoplastic compound aplidine, a new marine-derived depsipeptide, has shown preclinical activity in vitro on hematological and solid tumor cell lines. It is currently in early phase clinical trials. The exact mechanism of action of this anticancer agent still needs to be clarified," scientists writing in the British Journal of Cancer report.
"We have previously reported that aplidine blocks the secretion of the angiogenic factor vascular endothelial growth factor (VEGF) by the human leukemia cells MOLT-4, suggesting a possible effect on tumor angiogenesis. This study was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.